A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2016
At a glance
- Drugs Q 203 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors Qurient Co
- 01 Aug 2016 Status changed from active, no longer recruiting to completed.
- 30 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 May 2016 as reported by ClinicalTrials.gov.
- 21 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.